报价延迟最少15分钟:2025/09/18 05:43 EDT
盘前时段
|
||||
|
-- 
|
|
|
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
8.11
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-0.82/-0.61
|
|
企业价值
1.43B
|
| 资产负债 |
|
每股账面净值
6.61
|
| 现金流量 |
|
现金流量率
0.01
|
| 损益表 |
|
收益
660.57M
|
|
每股收益
4.45
|
|
同行比较
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
报价延迟最少15分钟：2025/09/18 05:43 EDT
同行比较之报价最少15分钟延迟
|
业务概览
|
|||
| NeoGenomics Inc provides oncology diagnostic testing and consultative services which include technical laboratory services and professional interpretation of laboratory test results by licensed physicians or molecular experts in pathology and oncology. It operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company operates in a single segment and derives revenue from clients by providing clinical cancer testing, interpretation, and consultative services, molecular and NGS testing, comprehensive technical and professional services offerings, clinical trials and research, validation laboratory services, and oncology data solutions. |
